University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > Treatment Guidelines
Adult Antiretroviral Treatment Guidelines
Pediatric Treatment Guidelines
Blood Testing Guidelines
Complications Guidelines
transparent image
Hepatitis Guidelines
transparent image
Tuberculosis Guidelines
Postexposure Guidelines
Primary Care
Sexually Transmitted Diseases
Testing for HIV Infection
Adult Antiretroviral Treatment Guidelines
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents -- A Working Group of the Office of AIDS Research Advisory Council (OARAC). See also slide sets from the AETC National Resource Center.
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. PDF versions available [1.2MB ]. Training slides on perinatal guidelines are also available.
Antiretroviral Treatment of Adult HIV Infection
2010 Recommendations of the International AIDS Society-USA Panel. JAMA. 2010;304(3):321-333.
Guidelines for Improving Entry into and Retention in Care and Antiretroviral Adherence for Persons with HIV: Evidence-Based Recommendations from an International Association of Physicians in AIDS Care Panel
Thompson MA, Mugavero MJ, Amico KR, et al. Ann Intern Med. 5 June 2012;156(11):817-833.
Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2008 Recommendations of an International AIDS Society-USA Panel
Clin Infect Dis. 2008 Jul 15;47(2):266-85. See also Update of the Drug Resistance Mutations in HIV-1: March 2013, Top Antivir Med. 2013 Feb-Mar;21(1):6-14.
Adapting Your Practice: Treatment and Recommendations for Homeless Patients with HIV/AIDS
Health Care for the Homeless Clinicians' Network, 2008. [PDF, 694K]
Pediatric Treatment Guidelines
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, Health Resources and Services Administration (HRSA), and National Institutes of Health (NIH). Also available, related slide sets from the AETC National Resource Center.
Blood Testing Guidelines
Guidelines for Performing Single-Platform Absolute CD4+ T-Cell Determinations with CD45 Gating for Persons Infected with Human Immunodeficiency Virus
Centers for Disease Control and Prevention, MMWR 2003;52(No. RR-2):1-13. [PDF version, 397K]
Guidance for Industry: Availability of Licensed Donor Screening Tests Labeled for Use with Cadaveric Blood Specimens
Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, June 2000. [PDF version]
Revised Guidelines for Performing CD4+ T-Cell Determinations in Persons Infected with Human Immunodeficiency Virus (HIV)
Centers for Disease Control and Prevention, MMWR 1997;46(No. RR-2):1-29.
U.S. Public Health Service Guidelines for Testing and Counseling Blood and Plasma Donors for Human Immunodeficiency Virus Type 1 Antigen
Centers for Disease Control and Prevention, MMWR 1996;45(No. RR-2):1-9.
Complications Guidelines

(Treatment/Prevention of Opportunistic/Comorbid Infections and Malignancies, Adverse Effects of Therapy, and Other Complications)

Guidelines for Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children
Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Infectious Diseases Society of America (IDSA).
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
Recommendations of the CDC, the National Institutes of Health, and the Infectious Diseases Society of America.
The Immunocompromised Traveler
Centers for Disease Control and Prevention Travelers' Health website. Includes vaccination recommendations. Accessed December 2007.
Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients
Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America, Clinical Infectious Diseases 2005; 40:1559-85.
Management of Metabolic Complications Associated with Antiretroviral Therapy for HIV-1 Infection
Recommendations of an International AIDS Society-USA Panel, JAIDS, November 1, 2002.
Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
Clinical Infectious Diseases 2003;37:613-627.
Hepatitis Guidelines
Guidelines for Laboratory Testing and Result Reporting of Antibody to Hepatitis C Virus Centers for Disease Control and Prevention, MMWR 2003;52(No. RR-3):1-16. [PDF version, 2.1MB]
Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings Centers for Disease Control and Prevention, MMWR 2003;52(No. RR-1):1-33. [PDF version, 465K]
Appendix: Hepatitis A and B Vaccines Centers for Disease Control and Prevention, MMWR 2003;52(No. RR-1):34-36.
Management and Treatment of Hepatitis C Viral Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office
Am J Gastroenterol 2006;101:2360-2378.
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis Centers for Disease Control and Prevention, MMWR 2001;50(No. RR-11):1-42. [ PDF version, 321K]
Appendix A. Practice Recommendations for Health-Care Facilities Implementing the U.S. Public Health Service Guidelines for Management of Occupational Exposures to Bloodborne Pathogens Centers for Disease Control and Prevention, MMWR 2001;50(No. RR-11):43-44.
Appendix B: Management of Occupational Blood Exposures Centers for Disease Control and Prevention, MMWR 2001;50(No. RR-11):45-46.
Appendix C: Basic and Expanded HIV Postexposure Prophylaxis Regimens Centers for Disease Control and Prevention, MMWR 2001;50(No. RR-11):47-52.
Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Centers for Disease Control and Prevention, MMWR 1999;48(No. RR-12):1-37.
Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease
Centers for Disease Control and Prevention, MMWR 1998;47(No. RR-19):1-39.
Public Health Service Inter-Agency Guidelines for Screening Donors of Blood, Plasma, Organs, Tissues, and Semen for Evidence of Hepatitis B and Hepatitis C
Centers for Disease Control and Prevention, MMWR 1991;40(No. RR-4):1-17.
Tuberculosis Guidelines
Treatment of Tuberculosis
American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. MMWR 2003;5(No.RR-11):1-77.
Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors
Centers for Disease and Prevention Control, Division of Tuberculosis Elimination, January 20, 2004.
Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003
Centers for Disease Control and Prevention, MMWR 2003;52:735-739.
Guidelines for Using the QuantiFERON-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection
Centers for Disease Control and Prevention, MMWR 2003;52(No. RR-02):15-18. [PDF version, 397K]
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
Centers for Disease Control and Prevention, MMWR 2000;49(No. RR-06):1-54.
Anergy Skin Testing and Preventive Therapy for HIV-Infected Persons: Revised Recommendations
Centers for Disease Control and Prevention, MMWR 1997;46(No. RR-15):1-10.
Postexposure Guidelines
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis
Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, Gomaa A, and Panlilio AL. Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92.
Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States
Centers for Disease Control and Prevention, MMWR 2005;54(No. RR-02):1-20. See also related slide set from the AETC National Resource Center.
Post-Exposure Prophylaxis Guidelines
New York State Department of Health AIDS Institute, December 2005.
Offering HIV Prophylaxis Following Sexual Assault: Recommendations for the State of California
Joan E. Myles, Joshua Bamberger. Housing and Urban Health of the San Francisco Department of Public Health and The California HIV PEP After Sexual Assault Task Force in Conjunction with the California State Office of AIDS, June 2004. [PDF, 218K]
Primary Care
Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Judith A. Aberg, Jonathan E. Kaplan, Howard Libman, Patricia Emmanuel, Jean R. Anderson, Valerie E. Stone, James M. Oleske, Judith S. Currier, and Joel E. Gallant. Infectious Diseases Society of America. Clinical Infectious Disease 49. September 1, 2009. [PDF, 260K]
Sexually Transmitted Diseases
Sexually Transmitted Diseases Treatment Guidelines, 2010
Centers for Disease Control and Prevention, MMWR December 17, 2010;59(RR12):1-110.
Testing for HIV Infection
Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings
Centers for Disease Control and Prevention, MMWR 2006;55(RR14);1-17. See also related slide sets from the CDC. [PowerPoint, 1.8MB]